VGF Protein and Its C-Terminal Derived Peptides in Amyotrophic Lateral Sclerosis: Human and Animal Model Studies. by Brancia, C et al.
RESEARCH ARTICLE
VGF Protein and Its C-Terminal Derived
Peptides in Amyotrophic Lateral Sclerosis:
Human and AnimalModel Studies
Carla Brancia1*, Barbara Noli1, Marina Boido2, Andrea Boi1, Roberta Puddu3,
Giuseppe Borghero3, Francesco Marrosu3, Paolo Bongioanni4, Sandro Orru`5,
Barbara Manconi6, Filomena D’Amato1, Irene Messana8, Federica Vincenzoni7,
Alessandro Vercelli2, Gian-Luca Ferri1‡, Cristina Cocco1‡
1 NEF-Laboratory, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy,
2 Neuroscience Institute Cavalieri Ottolenghi, Department of Neuroscience, University of Turin, Turin, Italy,
3 Department of Neurology, Azienda Universitario Ospedaliera di Cagliari and University of Cagliari,
Cagliari, Italy, 4 Neurorehabilitation Unit, Neuroscience Department, University of Pisa, Pisa, Italy,
5 Medical Genetics, Department of Medical Sciences, University of Cagliari, Binaghi Hospital, Cagliari, Italy,
6 Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy, 7 Institute of
Biochemistry and Clinical Biochemistry, Catholic University, Rome, Italy, 8 Institute of Chemistry of the
Molecular Recognition CNR, Rome, Italy
‡ These authors are co-senior authors on this work.
* cbrancia@unica.it
Abstract
VGF mRNA is widely expressed in areas of the nervous system known to degenerate in
Amyotrophic Lateral Sclerosis (ALS), including cerebral cortex, brainstem and spinal cord.
Despite certain VGF alterations are reported in animal models, little information is available
with respect to the ALS patients. We addressed VGF peptide changes in fibroblast cell cul-
tures and in plasma obtained from ALS patients, in parallel with spinal cord and plasma
samples from the G93A-SOD1 mouse model. Antisera specific for the C-terminal end of
the human and mouse VGF proteins, respectively, were used in immunohistochemistry
and enzyme-linked immunosorbent assay (ELISA), while gel chromatography and HPLC/
ESI-MS/MS were used to identify the VGF peptides present. Immunoreactive VGF C-termi-
nus peptides were reduced in both fibroblast and plasma samples from ALS patients in an
advanced stage of the disease. In the G93A-SOD1 mice, the same VGF peptides were
also decreased in plasma in the late-symptomatic stage, while showing an earlier down-
regulation in the spinal cord. In immunohistochemistry, a large number of gray matter struc-
tures were VGF C-terminus immunoreactive in control mice (including nerve terminals,
axons and a few perikarya identified as motoneurons), with a striking reduction already in
the pre-symptomatic stage. Through gel chromatography and spectrometry analysis, we
identified one form likely to be the VGF precursor as well as peptides containing the NAPP-
sequence in all tissues studied, while in the mice and fibroblasts, we revealed also AQEE-
and TLQP- peptides. Taken together, selective VGF fragment depletion may participate in
disease onset and/or progression of ALS.
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Introduction
Amyotrophic Lateral Sclerosis (ALS) is a progressive and fatal neurodegenerative disorder
characterized by selective degeneration and death of upper and lower motor neurons, respec-
tively, in the cerebral cortex, brainstem and spinal cord. Vgf is a neutrophin induced gene that
encodes for a single VGF precursor, composed of 617 (rat/mouse) / 615 (human) amino acids
[1]. Studies in rats revealed that VGF mRNA is widely expressed in areas that are known to
degenerate in ALS, including cerebral cortex, spinal cord, and cranial nervemotor nuclei as tri-
geminal and hypoglossal nuclei [2]. While the role of VGF in the nervous system is yet to be
clarified, in VGF knock-outmice, synaptic plasticity and memory would be affected, in addi-
tion to a depressive behaviour [3]. VGF cleavage can gives rise to a variety of bioactive peptides,
of which those derived from its C-terminal portion have so far beenmore extensively studied.
Two peptides from such region, named AQEE-30 and TLQP-62 appear to regulate synaptic
function [4], while TLQP-62 can also induce neurogenesis [5], or enhance neuronal hippocam-
pal transmission [6], and would be required for hippocampal memory consolidation [7]. In the
most commonly usedmurine model of ALS, i.e G93A-SOD1 transgenic mice overexpressing
the mutated human SOD1 gene, VGF immunoreactivity was reported to be reduced in the cer-
ebro-spinal fluid (CSF) and serum, as in the spinal cord in parallel with the progression of mus-
cle weakness [8]. In CSF from ALS patients, a VGF-derived 4.8 kDa fragment significantly
decreased compared to controls [9], while immunoreactivity of the VGF full-lengthwas
reduced in parallel with development of ALS symptoms [8]. Moreover, the density of VGF
immunoreactivity was also lower in spinal cords from sporadic ALS patients than in control
subjects [10]. Interestingly, increasedVGF expression would attenuate excitotoxic injury in
primarymixed spinal cord cultures from G93A-SOD1 mice [8]. VGF could be also involved in
neuroprotective mechanisms in stress-induced cell death in vitro as well as in vivo [10]. Recent
literature data showed as human primary fibroblast cultures from ALS patients reflect some
pathophysiological features observed in neuronal cells [11], with altered bioenergetic properties
in neurodegenerative diseases, including ALS [12, 13]. Hence, we decided to use both patients’
plasma and fibroblasts to search for evidence of VGF changes. In order to confirm and extend
our study, we also analysed the G93A-SOD1 animal model (spinal cord and plasma). Highly
characterizedVGF antisera raised against the human and mouse C-terminal end of the VGF
were used in immunohistochemistry (IHC) and enzyme-linked immunosorbent assay
(ELISA), while gel chromatography and HPLC high-resolution Electron Spray Ionization-MS
(HPLC-ESI-MS) and HPLC/ESI-MS/MS (MS/MS) were carried out to identify VGF peptides
present.
Materials and Methods
VGF Antibodies
We produced two different policlonal VGF antisera against the following human and rat/
mouse proVGF C-terminal sequences: (I) human VGF607-615: -I EHVL LRRP [14] and (II) rat/
mouse VGF609-617: -I EHVL LHRP [15]. The relevant rat and human nonapeptide antigens
were synthesized by Affiniti-Biomol, Exeter, Devon, UK and conjugated to bovine thyroglobu-
lin via an additional N-terminal D-tyrosine for immunizations. Characterization of both anti-
bodies has been previously described in detail [16–19].
Human plasma
The plasma samples included either female (n = 18) or male (n = 23) ALS patients and age-
matched control subjects (n = 45), ranging 25–85 yrs and collected between 2012–14 at the
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Department of Neurology, Azienda Universitaria-Ospedaliera of Cagliari and University of
Cagliari. All participants provided their written informed consent, and the study was approved
by the Ethical Committee of Cagliari AOU (“Azienda OspedalieraUniversitaria”), protocol n.
450/09/C.E. The groups of patients analysed included subjects with TDP-43 mutation (n = 19),
G93A-SOD1 (n = 3), expansion in C9ORF72 gene (n = 3) or unidentified aetiology (n = 16).
At the time of blood sampling, the patients’ motor and functional status were assessed by
neurologists using the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised
(ALSFRS-R [20]). Patients’ scores are reported in supporting information (S1 Dataset).
On the basis of their survival and/or clinical state one year after the above blood sampling,
patients were assigned to either of two “outcome groups”: (i) “early stage” (n = 23), alive
patients which had not yet required tracheostomy; or (ii) “advanced stage” (n = 18), including
patients, which had required tracheostomy, or were deceased.
Human fibroblasts
Primary fibroblast cell cultures were derived from skin biopsies taken with informed consent
from: ALS patients at the advanced phase with (I) heterozygous missense TARBDP-A382T
mutation TARBDP-A382T; (n = 2), (II) WT genotype at the TARDBP, FUS or C9orf72 loci
(n = 2), all compared with healthy age-matched control subjects (n = 3). The use of fibroblast
samples was approved by the local ethics committee. Cells were grown in high-glucoseDMEM
supplemented with 20% (vol/vol) fetal bovine serum, 1% penicillin/streptomycin (10,000 units
penicillin and 10 mg streptomycin per mL in 0,9% NaCl) (all from Sigma Aldrich, ST). For
immunocytochemistry, the cells were grown on glass coverslips and fixed after treatment in 4%
w/v paraformaldehyde (PFA) for 15 min., permeabilizedwith cold methanol for 5 min. and
0.2% Triton X-100 in phosphate-buffered saline (PBS, 0.01 mol/l PO4, pH 7.4) for 20 min.
Cells were then incubated for 4h at room temperature with human VGF C-terminus (1:1000)
diluted in PBS containing 30ml/l of normal donkey serum and immunoreactivity was revealed
with specific donkey secondary antisera conjugated with Cy3. Nuclei were counterstained with
Hoechst 33342 (Sigma Aldrich). Coverslips were mounted with Glycerol/PBS (1:1). Negative
controls were routinely performed for each experiment, incubating the samples with non-
immune serum and/or with the appropriate secondary antisera. Imaging was carried out using
an Olympus BX41 fluorescencemicroscope. For ELISA and gel chromatography, the cells were
extractedwith PBS-PIC (protease inhibitor cocktail: P8340, Sigma-Aldrich, Schnelldorf, Ger-
many). Since there was not other evidence of the presence of VGF in fibroblasts, the expression
of the VGF gene at the level of mRNA was studied by RT-PCR amplification using both patient
and control samples. Briefly: 0.5–1μg of total RNA was reverse transcribed to cDNA using the
ThermoScript™ RT-PCR System for First-Strand cDNA Synthesis (Invitrogen). Two ul of final
reaction were used for amplifying a fragment of 160 bp of the VGF gene. The reaction was car-
ried out in 25 μl final volume using the primer pair VGF77 (GACCTCGACCGTCGCTCC) and
VGF241 (GCCGACAATCTGAGGGCTTT). HPRT was used as a housekeeping control gene
and amplified using the primer pair HumHPRT.1 (CCCTGGCGTCGTGATTAGTG) and
HumHPRT.2 (CGAGCAAGACGTTCAGTCCT). Specific primers for the human VGF gene were
designed using primer-Blast (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and validated
by RT-PCR carried out on cDNA from SY5Y Human cell lines.
Animal Model
The experiments were performed on transgenic male mice B6SJL-TgN(SOD1-G93A)1Gur
over-expressing human SOD1, containing the Gly93 to Ala mutation (Jackson Laboratory, Bar
Harbor, ME, USA; stock number 002726); these mice have a high transgene copy number. The
VGF C-Terminal Derived Peptides in ALS
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founders were kindly gifted by M. Bentivoglio and R.Mariotti (University of Verona). The col-
ony was derived from breedingmale transgenic mice to naive (B6xSJL/J)F1 females (Janvier
SAS, Le Genest-Saint-Isle, France). All experimental procedures on live animals were carried
out in accordance with the European Communities Council Directive 86/609/EEC (November
24, 1986) Italian Ministry of Health and University of Turin institutional guidelines on animal
welfare (law 116/92 on Care and Protection of living animals undergoing experimental or
other scientific procedures; authorization number 17/2010-B, June 30, 2010). Additionally, the
Ethical Committee of the University of Turin approved this study. All efforts were made to
minimize the number of animals used and their suffering. For the genotyping, a 0.5 cm-long
specimen of mouse tail was incubated in 100 μl of lysis buffer (10 mM Tris HCl, 50 mMKCl,
0.01% gelatin, 0.45% IGEPAL, 0.4% Tween-20) and 25 μg of proteinase k at 55°C, overnight,
under gentle shaking, in order to extract the DNA. Then, PCR was performed to evaluate the
presence of the human transgene superoxide dismutase-1 (hSOD1). As suggested by the sup-
plier, the employed primers were: 5’-CATCAGCCCTAATCCATCTGA-3’ and 5’-CGCGACT
AACAATCAAAGTGA-3’ for hSOD1 gene; while 5’-CTAGGCCACAGAATTGAAAGATCT-3’
and 5 GTAGGTGGAAATTCTAG CATCATCC-3’ for mouse interleukin 2 gene, as internal con-
trol. To characterize the time course and the progression of ALS symptoms, transgenic (TG)
mice were weighedweekly and underwent a battery of behavioral tests, starting from the pre-
symptomatic phase: neurological test, rotarod and paw grip endurance (PaGE) tests. All tests
have been extensively described in Boido et al. [21]. TG animals were subdivided into the fol-
lowing three groups, according to the stage of motor dysfunction progression and to their post-
natal (P) days: (i) pre-symptomatic (around P45), (ii) early-symptomatic (around P90; two
repeated deficits for two consecutive times) and (iii) late-symptomatic (around P120; 20%
weight decrease and inability in performing tests). Age-matched wild type mice (WT) were
used as controls.
Tissue sampling
For ELISA, at each time point, mice (n = 7 per genotype) were euthanized by cervical disloca-
tion, and cervical spinal cords were dissected. Tissues were extracted with ice-cold PBS, con-
taining PIC and homogenized for 3 min. using a micro sample pestle, hence tubes were heated
in a vigorously boiling water bath for 10 min., and centrifuged (3,000 rpm, 15 min.). Superna-
tants were stored frozen until use (−20°C). From the same mice, blood (approximately 200μl)
was drawn under terminal anesthesia by cardiac puncture, collected in a tube containing ethyl-
enediaminetetraaceticacid (EDTA, 178 mg/ml), and rapidly centrifuged (11,000 rpm, 5 min.),
hence plasma was stored frozen (-80°C). For IHC, at each time point, mice (n = 3 per genotype)
were deeply anaesthetized by gaseous anaesthesia (3% isoflurane vaporized in O2/N2O 50:50),
underwent intracardiac perfusionwith 4% PFA, pH 7.4. The whole spinal cords were removed
and post-fixed in PFA for 2 h at 4°C. After fixation, cervical segments of spinal cords were
included in an embeddingmedium [22] and cut (at 10μm) using a HM-560 cryomicrotome
(Microm;Walldorf, Germany).
ELISA
Competitive ELISA was performed through VGF assays previously used with human and
mouse tissues [18]. Multiwell plates (Nunc, Milan, Italy) were coated with the relevant syn-
thetic peptides and treated with PBS (containing 9% normal serum from the secondary antisera
donor species, 20nM aprotinin, and 1mg/ml EDTA) for 2 hours. Primary incubations, with
either human or rat/mouse VGF C-terminus antiserum, were carried out in duplicate, includ-
ing serial standard dilutions in parallel with samples from human (plasma, fibroblasts) or
VGF C-Terminal Derived Peptides in ALS
PLOS ONE | DOI:10.1371/journal.pone.0164689 October 13, 2016 4 / 16
mouse (spinal cord, plasma). Biotinylated secondary antibodies (Jackson, West Grove, PA,
USA), streptavidin-peroxidase conjugate (Biospa, Milan, Italy), and tetrametylbenzidine (TMB
X-traKem-En-Tec, Taastrup, Denmank) as substrate were used to reveal the positive labelling.
Hence, the reaction was stopped with HCL (1mol/L) and the optical density was measured at
450nm using a multilabel plate reader (Chameleon: Hidex, Turku, Finland). Recovery of syn-
thetic peptide/s added to plasma, or to tissue samples at extractionwas>85% for all assays
used. Each VGF assay was characterized using various synthetic peptides. Inter (CV1) and
intra (CV2) assays were 3–4% and 9–11%, respectively. Data were expressed as mean ± SEM
throughout.
Statistical analysis
For ELISA data, statistical analyses were carried out by one-way ANOVA, followed by post hoc
multiple comparison tests (Student-Newman-Keul test), or by two-tailed Student’s t-test as
appropriate by means of the StatistiXL software. Linear regression analysis was used to estimate
the possible correlation between the VGF levels and the ALSFRS-R values. P-value < 0.05 was
considered significant.
Immunohistochemistry
Sections of mouse spinal cord samples were incubated overnight in a humid chamber, with the
mouse VGF C-terminus primary antiserum diluted (1:4000) in PBS containing 30ml/l of nor-
mal donkey serum, 30 ml/l of normal mouse serum and 0.02g/l NaN3. Double immunofluores-
cence experiments were carried out mixing the anti VGF antiserumwith the anti rat/mouse
VAChT antibody (vesicular acetylcholine transporter; BIOMOL Research lab, Plymouth Meet-
ing, PA; 1:400 dilution), raised in different donor species (rabbit and goat, respectively). The
relevant species-specificdonkey secondary antisera, conjugated with either Alexa-488 (emit-
ting in green; 1:200) and or cyanin 3.18 (yellow/red; 1:300) (Jackson Immunoresearch Labora-
tories,West Grove, PA) were used to reveal immunoreactivity of the primary antisera. Slides
were covered with PBS-glycerol (40%), observedand photographed using BX41 and BX51 fluo-
rescencemicroscopes (Olympus, Milan, Italy) equipped with the Fuji S2 and S3 Pro digital
cameras (Fujifilm,Milan, Italy). Routine controls included substitution of each antiserum, in
turn, with PBS, the use of pre-immune or non-immune sera, and the testing of each secondary
antiserumwith the respective non-relevant primary antibody.
Gel Chromatography, HPLC high-resolution ESI-MS and MS/MS
analysis
To reveal the MW of the VGF fragments present in the tissues studied, we used a gel chroma-
tography approach that can easily isolate highMW forms (up to 70kDa), including the VGF
precursor, but also smaller VGF fragments. In order to validate the findings, we also used
HPLC high-resolution ESI-MS to reveal the specific VGF peptide sequences, at least in the
mouse spinal cord. For gel chromatography analysis, cervical spinal cord extracts (1.6 mL) and
plasma (1mL), both pooled from control mice, as well as plasma (3 mL), and fibroblasts
(1.5mL) from control subjects, were individually loaded onto a Sephadex G-50S column
(Sigma; 2cm2 x 1m). This column was equilibrated with 50 mM ammonium bicarbonate and
eluted with the same buffer. A MWmarker kit (MWGF70, Sigma) was used for the column cal-
ibration. The collected fractions (3 mL) were reduced in volume with a vacufuge concentrator
(Eppendorf, Milan, Italy) and assessed by ELISA. The overall recovery of loaded immunoreac-
tivity ranged between 80% and 100%. For HPLC high-resolution ESI-MS and MS/MS analysis,
the cervical spinal cord extracts from control mice were fractionated by using 10kDa cutoff
VGF C-Terminal Derived Peptides in ALS
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Amicon Ultra devices (Merck Millipore, Tullagreen Carrigtwohill Co. Cork, Ireland). Frac-
tions<10kDa were dried in a Vacufuge Concentrator (Eppendorf, Milan, Italy), and a total of
5 μg was resuspended in 50 μl of aqueous formic acid solution (0.1% v/v) and 1 μg analyzed
using an Ultimate 3000 RSLCnano coupled with an Orbitrap Elite mass spectrometer (Ther-
moFisher, San Jose, CA). Separation experiments were performed using an EASY-Spray Col-
umn PepMap1 RSLC C18 (3 μm particle diameter; column dimension 75 μm ID x 15 cm)
with the following eluents: (A) 0.1% (v/v) aqueous formic acid and (B) acetonitrile with 0.1%
(v/v) aqueous formic acid. The applied gradient was linear from 0 to 55% of solvent B in 35
min, at a flow rate of 300 nL/min. The Elite-Orbitrap mass spectrometer operated in a data-
dependent mode in which each full MS scan (60 000 resolving power) was followed by five MS/
MS scans where the first five multiple-charged ions were dynamically selected and fragmented
by collision-induceddissociation (CID) at a normalized collision energy of 35%. Tandem mass
spectra were analysed using the Thermo Proteome Discoverer 1.4 software, and the SEQUEST
cluster (University of Washington, Seattle, WA, licensed by Thermo Electron Corp) was used
as search engine against UniProtKB mouse proteome (releases 2016–03). For peptidematching
the following limits were used: Xcorr scores greater than 1.5 for singly charged peptide ions
and 2.0 and 2.5 for doubly and triply charged ions, respectively. Precursor mass search toler-
ance was set to 10 ppm, and fragment mass tolerance was set to 0.02 Da. N-Terminal Modifica-
tion (Gln! pyro-Glu) and C-Terminal Modification (Amidated) were chosen as dynamic
modifications. A false discovery rate (FDR) below 1% was applied. Peptide sequences and sites
of covalent modificationswere also validated by manual spectra annotation performedby com-
paring experimentalMS/MS spectra with the theoretical generated by the MS-Product pro-
gram available on Protein Prospector website (http://us.expasy.org/tools). The match was
considered positive when all the experimentalm/z values with a relative abundance higher
than 5% were present in the theoretical fragmentation spectrum, and when differences between
the experimental and theoretical values were less than ± 0.03 m/z.
Results
VGF changes in human
Using plasma samples (Fig 1A), we found that VGF C-terminus peptide levels were decreased
in ALS patients at the advanced stage (percentage decrease: 16%, p<0.04) compared to controls
and patients at the early stage. We also found a VGF C-terminus reduction in fibroblasts (Fig
1B) obtained from ALS patients at the advanced stage, with either TDP-43 mutation or uniden-
tified aetiology (percentage decrease: 47% p<0.04; 51%, p<0.02, respectively), compared to the
control cells Raw data from ELISA are reported in S2 Dataset. Instead, the mRNA of the VGF
gene was revealed in cells from both patients and controls (not shown). However, due to the
very low levels of transcription, all attempts to quantify changes in mRNA levels by Real-Time
PCR, have not produced consistent results. Immunocytochemistry (Fig 1C and 1D) revealed
the VGF localization into the cytoplasm, close to the nucleus and probably identified as Golgi
area, with no differences between control (Fig 1C) and ALS patient (Fig 1D) derived cells.
Molecular characterization in human
Molecular characterization by ELISA coupled with gel chromatography showed that in both
plasma and fibroblasts (Fig 2A and 2B) VGF C-terminus antiserum recognized two fragments,
one of 66kDa likely to be the VGF precursor or a highMWVGF protein, and an additional
form of 14–15 kDa encompassing a peptide containing the sequence fromNAPP up to the C-
terminus, made of 129 aa, hence namely NAPP-129. Moreover, in human fibroblasts we
revealed also additional forms of: (a) 8kDa corresponding to the TLQP-62, (b) 3–4 kDa,
VGF C-Terminal Derived Peptides in ALS
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corresponding to the AQEE-30 and (c) one uncharacterized form of 1.3 kDa. It has to be noted
that the name of the VGF peptides is expressed here using the single-letter codes of the first
four amino acids (at the peptide N-terminus), followed by the number of amino acid residues.
The MW forms revealed in human tissues are summarized in Table 1.
VGF levels and ALS Functional Rating Scale
We analysed patients in order to correlate the VGF C-terminus levels with the ALSFRS-R val-
ues. We observed a no statistically significant linear relationship (p = 0.58, r = 0.086) between
VGF levels and ALSFRS-R values (S1 Fig). At the time of blood sampling, the two groups had
not significant differences in their ALSFRS-R values (p = 0.091).
VGF changes in mouse
In mouse plasma (Fig 3A), we found a VGF C-terminus immunoreactivity reduction in the
late-symptomatic phase of the G93A-SOD1 mice, (percentage decrease: 43%, p<0.01), com-
pared to their normal littermates. In the spinal cord instead (Fig 3B), VGF C-terminus
Fig 1. VGF C-terminus peptide changes in human. In plasma (A), ALS patients reveal a reduction in the VGF C-terminus peptide
levels seen in the late stage (n = 18) compared to the controls (n = 45) and patients at the early stage (n = 23) (mean ± SEM; percentage
of decrease: 16%, p<0.04). In human fibroblasts (B) taken from patients at the late stage of disease, VGF C-terminus peptide levels are
significant decreased irrespective to the mutation (mean ± SEM; percentage of decrease 47% p<0.04; 51%, p<0.02 for TDP-43 and
unknown etiology, respectively). Values (from 3 sets of experiments for each tissue) are expressed as percent of control level.
Immunocitochemistry (C, D) shows the localization of VGF C-terminus peptides into the cytoplasm and especially within the vesicular
membrane system in both controls (C) and ALS patients (D). No changes in the VGF immunolocalization were seen between ALS
patients and controls. VGF: yellow/red (Cy3), hoechst 33342 (blue): nucleus. Data referring to 4 sets of experiments. Scale bar: 10μm.
doi:10.1371/journal.pone.0164689.g001
VGF C-Terminal Derived Peptides in ALS
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immunoreactivity was significantly decreased already in the early-symptomatic phase (62%
reduction, p<0.004,), and remained down-regulated in the late-symptomatic phase (65%
reduction, p<0.03,) of the G93A-SOD1 mice as compared to their normal littermates. Raw
data from ELISA are reported in S2 Dataset. In immunohistochemistry (Fig 3C), at either pre-
or late- symptomatic stage of theWTmice, VGF C-terminus antiserum labelled a large num-
ber of nerve terminals and axons through the entire grey matter including the ventral and dor-
sal horns. Few perikaryawere also labelled within the lamina X surrounding the central canal,
as well as within the ventral horns. In the G93A-SOD1 mice instead, the VGF C-terminus
immunoreactivity was reduced already in the pre-symptomatic stage. The lack of the VGF
immunoreactivity was observedwithin the entire grey matter, including ventral and dorsal
horns, and was equally slight also in the late-symptomatic stage. In order to identify the motor
neuronal phenotype of the VGF reactive perikarya in the ventral horns, we also carried out
double staining mixing the VGF C-terminus and VAChT antibodies (Fig 4). In theWTmice,
almost all the cell bodies positive for the VGF antiserum in the ventral horns were identified as
motor neurons. As expected, the general scarcity of VGF immunoreactivity in the pre-
Fig 2. Molecular characterization in human. ELISA coupled with gel chromatography reveals two MW forms of approximately 66 and
14–15 kDa, recognised by the VGF antibody in both plasma (A) and fibroblasts (B), where additional MW forms of 8 kDa, 3–4 kDa, and
1.3–2kDa were also revealed. Result data referred to 3 sets of experiments, using control animal only.
doi:10.1371/journal.pone.0164689.g002
Table 1. VGF C-terminus fragments found by gel chromatography in human.
Tissue VGF fragment Sequence MW (kDa)
Plasma VGF protein VGF1-615* 66
NAPP-129 VGF485-615 14–15
Fibroblasts VGF protein VGF1-615* 66
NAPP-129 VGF485-615 14–15
TLQP-62 VGF554-615 8
AQEE-30 VGF586-615 3–4
MW: molecular weight;
*VGF precursor or a high MW VGF form
doi:10.1371/journal.pone.0164689.t001
VGF C-Terminal Derived Peptides in ALS
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Fig 3. VGF C-terminus peptide changes in mouse. In plasma (A), the G93A-SOD1 mice show a VGF reduction revealed in the late
symptomatic phase compared to the WT mice (43% reduction, p<0.01, data from 3 sets of experiments), while, in the spinal cord (B), a
loss of immunoreactivity is shown since in the early- other than in the late-symptomatic phases of G93A-SOD1 mice compared to the
corresponding WT (**p<0.004 and *p<0.03, respectively; from 3 sets of experiments). In immunohistochemistry, (C) the WT mice (at
both pre- and late-symptomatic stages, n = 3 animals per each group), reveal a bright VGF C-terminus immunoreactivity, widely
distributed in a high number of nerve structures (terminals, axons, dendrites) within the entire gray matter, including the ventral and
dorsal horns and near the III ventricle. Instead, VGF immunostaining disappears in almost all nerve structures in the G93A-SOD1 mice,
already in the pre-symptomatic stage (result data from 4 sets of experiments for each case). Scale bars: 100 μm.
doi:10.1371/journal.pone.0164689.g003
VGF C-Terminal Derived Peptides in ALS
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symptomatic stage of the G93A-SOD1 mice, included the motor neurons that were reduced in
number and/or brightness while the VAChT labelling remained visible.
Molecular characterization in mouse
Gel chromatography coupled with ELISA, in plasma (Fig 5A) and spinal cord (Fig 5B) revealed
the same two forms of 66 and 14–15 kDa corresponding to proVGF and NAPP-129, seen in
human tissues (both plasma and fibloblasts).Moreover, exclusively in the plasma, we also
revealed the same forms seen in fibroblasts and corresponding to TLQP-62, and AQEE-30 as
well as one uncharacterized form of 1.5–2 kDa. As mentioned (see materials and methods), to
reveal VGF peptide sequences in the mouse spinal cord, we also used the HPLC high-resolu-
tion ESI-MS in order to validate the gel chromatography findings. Hence, using HPLC-ESI-MS
we revealed short peptides, including two of 1.54 and 2.5kDa, namely AQEE-13, and NAPP-
19, respectively, largely encompassing the sequences revealed by gel chromatography, but trun-
cated at their C-terminus, and, a novel peptide of 2.5kDa that we called ELQE-20. The MW
forms revealed in mouse tissues are summarized in Table 2. The results of HPLC-ESI-MS/MS
experiments, and annotated spectra are reported in S3 Dataset.
Discussion
We report here the first evidence of a VGF down-regulation in both plasma and fibroblasts
from ALS patients, occurred at the advanced disease phase. These findings are supported by
Fig 4. Phenotype of the VGF immunoreactive perikarya. Immunohistochemistry in the ventral horn (A), reveals that in the WT mice,
at the pre- symptomatic stage, the VGF antibody labels a number of cell bodies other than axons and terminals. The VAChT instead
stains exclusively perikarya in a large number and with a punctate labeling around the cell membranes. All perikarya positive for the VGF
antibody were identified as motor neurons (merge panel) by the VAChT labelling (arrows identify the cell bodies positive for both
antibodies). Instead, in the G93A-SOD1 mice, at the same pre-symptomatic stage, the VGF staining is strikingly reduced also in motor
neurons while the VAChT staining instead, remains visible. The cell body feebly reactive for VGF is identified as motor neuron through a
double staining. Red (Cy3) and green (Alexa-488) staining: VGF C-terminus and VAChT, respectively. Result data are from 4 sets of
experiments for each case. Scale bars: 50 μm.
doi:10.1371/journal.pone.0164689.g004
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the decrease in the VGF levels showed also in plasma from the ALS mouse model. However, in
mice, reduced plasma VGF levels during the late phase were preceded by an early VGF down-
regulation in the spinal cord.
VGF in ALS patients
We describe here the first evidence of VGF changes in plasma and fibroblasts from ALS
patients. Indeed, the previous studies were so far carried out exclusively using CSF, reporting
changes related to either the VGF full length (hence containing the C-terminus portion) [8], or
one VGF fragment of 4.8 kDa not containing the C-terminus portion [9]. However, while in
our study, the plasma VGF content decreased at a late phase of the disease, the above men-
tioned studies using CSF, reported a reduction seen at the early stage. Hence, it seems that the
VGF reduction occurs first in the CSF and afterward in the plasma. Hence, since the VGF levels
were decreased in the advanced group without a statistically significant linear relationship with
the functional rating scale, it seems that VGF could be associated with the ensuing progression,
Fig 5. Molecular characterization in mouse. Gel chromatography coupled with ELISA reveals two MW forms of 66 and 14–
15 kDa revealed in both plasma (A) and spinal cord (B) plus the following forms of 8, 3–4, and 1.3–2 kDa, visible in plasma
only. Result data are from 3 sets of experiments per each tissue, using control animal only. Values are expressed as percent
of control level (mean ± SEM).
doi:10.1371/journal.pone.0164689.g005
Table 2. VGF C-terminus fragments found in mouse.
Tissue VGF fragment Sequence MW (kDa) Method
Plasma VGF protein VGF1-617* 66 SEC + ELISA
NAPP-129 VGF489-617 14–15 SEC + ELISA
TLQP-62 VGF556-617 8 SEC + ELISA
AQEE-30 VGF588-617 3–4 SEC + ELISA
Spinal cord VGF protein VGF1-617* 66 SEC + ELISA
NAPP-129 VGF489-617 14–15 SEC + ELISA
NAPP-19 VGF489-507 1.9 HPLC-ESI-MS
AQEE-13 VGF588-600 1.54 HPLC-ESI-MS
ELQE-20 VGF353-372 2.5 HPLC-ESI-MS
MW: molecular weight; SEC: Size-exclusion chromatography, HPLC-ESI-MS:RP-HPLC high-resolution ESI-MS and MS/MS analysis
* VGF precursor or a high MW VGF form
doi:10.1371/journal.pone.0164689.t002
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rather than to the severity of the disease at the time of blood sampling. Frequently occurs that
one candidate biomarker is related exclusively to certain clinical aspects. For instance, the plas-
matic Cystatin C levels, were found useful as an indicator of the disease severity and the site of
symptom onset [23]. However, they were significantly changed not exclusively in ALS, but also
in other neurodegenerative diseases, failing to be identified as a diagnostic biomarker specific
for ALS [24]. At this point, one could speculate that, the combination of the VGF with a panel
of different biomarkers [25] perhaps including Cystatin, may constitute a better strategy to aid
the diagnosis and prognosis of ALS but also its severity classification, as well as predict its pro-
gression. However, the exact mechanisms behind the VGF correlation with the disease progres-
sion have not been conclusive, however the possible use of VGF as a prognostic factor should
be better elucidated. Further studies will be warranted, including the analysis of the other
neurodegenerative diseases to confirm the peculiarity of our changes in ALS.
The VGF changes in fibroblasts from ALS patients represent an intriguing and novel find-
ing, since fibroblasts from ALS patients reflect some pathophysiological features observed in
neuronal cells [11]. This is the first evidence of the presence of VGF mRNA, as well as VGF
protein and its peptides in the fibroblasts. Interestingly, changes in bioenergetic properties as
well as mitochondrial morphology and functionality have been found in fibroblasts from ALS
patients [26, 27]. Since VGF ablation affects mitochondrial morphology, and mitochondrial
number, at least in BAT [28], the VGF reduction in ALS fibroblasts could represent the starting
point for further studies in order to investigate the role of VGF in ALS-related mitochondria
mechanisms.
VGF in ALS mice
The VGF plasma reduction seen in mouse was similarly observed in human, however, our
result is not according with the previous study that revealed an “early” VGF decrease in the
serum from the same G93A-SOD1 mice [8]. These contrasting results are probably due to the
different antibodies used through, an antiserum against the AQEE-30 [8] versus our antiserum
raised against the nonapeptide encompassing the C-terminus portion.However, MW charac-
terization was not carried out in that study [8]. Instead, our VGF antibody recognisedAQEE
peptides but also the putative proVGF, plus other VGF peptides largely containing the C-ter-
minus portion. In the spinal cord of the G93A-SOD1, using IHC, we revealed the presence of
the VGF C-terminus immunoreactivity within the entire gray matter. This represents a novel
finding since in the previous study [8] the immunolocalization using an antibody against the
VGF N-terminus, was restricted to motor neurons. The hallmark of ALS is the selective dam-
age of the spinal cord motor neurons. however, sensory neuropathy, abnormalities in somato-
sensory evoked potentials, reduced spinal cord conduction velocity have also been detected in
up to 23% ALS patients [29–31] suggesting that ALS may be a multi-system neurodegenerative
disease. Furthermore, sensory impairment has been also reported in the SOD1-G93Amice rel-
atively early in disease progression [32]. Interestingly, in the dorsal horn, prolonged up-regula-
tion of VGF mRNA and VGF protein was observed in the rat spared injury model of
neuropathic pain [33]. It is conceivable that the early down-regulation of VGF protein in the
spinal cord may be related not only to the motor neuron degeneration, but also to other altered
spinal cord connections, including sensory pathways.
Identification of VGF protein and C-terminal peptides
In all tissues tested, we revealed the presence of a 66 kDa-VGF large protein, may compatible
to the VGF precursor as well as a MW fraction of 14–15kDamay compatible with the C-termi-
nus peptide that we calledNAPP-129 (from the NAPP sequence up to the C-terminus).
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However, to ensure our results, we also usedmass spectrometry in the spinal cord, keeping in
mind that it is unable to detect the sequences of large molecules as the VGF precursor (66Kda).
In the spinal cord, the mass spectrometry, revealed the presence of the NAPP-19. The NAPP-
19 [18], corresponds to the first 19 N-terminal amino acids of the larger size peptide, hypothe-
sized to be NAPP-129 by gel chromatography. Hence the mass spectrometry, as expected,
failed to reveal the VGF precursor, but ensures the gel chromatography results, at least in the
spinal cord. Moreover, the mass spectrometry, revealed also two further peptides: the AQEE-
13 a short peptide overlapping the N-terminus region of the AQEE-30 revealed by gel chroma-
tography in the mouse plasma, while the ELQE-20 is a VGF peptide recently identified in neu-
roblastoma cells [34]. By gel chromatography we also revealed further peptides, the TLQP-62
and AQEE-30, exclusively in fibroblasts and mouse plasma, suggesting a possible difference in
tissue-specificVGF processing. Besides, all the VGF peptides recognised by gel chromatogra-
phy, could be potentially involved in the changes that we revealed, hence hypothetically related
to the ALS pathological mechanisms.
Conclusions
We reported here a VGF down-regulation in ALS, probably due to the decrease of the large
VGF protein of 66kDa, and/or the other smaller C-terminal VGF peptides identified as NAPP-
129, TLQP-62, and AQEE-30. As mentioned, AQEE-30 and TLQP-62 peptides revealed bioac-
tivity into the nervous system [4, 5]. In particular, the TLQP-62 enhanced neuronal transmis-
sion through a BDNF dependent pathway [6, 7]. The correlation betweenVGF and BDNF, is
also ensured by the abnormalities in the VGF mutant mice that are associated with BDNF defi-
ciency [6], while vgfgene is up regulated by BDNF in association with synaptic plasticity [4].
Since neurotrophic factors are crucial for motor neuron survival [35], their decrease is one of
the hypothesized causes of the neuronal death in ALS [36]. Hence, it could be speculated that
the decrease in the C-terminal VGF peptides may participate in the ALS disease onset and/or
progression, through their alteration in BDNF related mechanisms. The understanding of the
bioactivity of the C-terminal VGF peptides in the spinal cord may increase the knowledge of
the ALS physiopathology mechanisms and may be useful for new therapeutic approaches. Fur-
thermore, since different peptides are produced from the same VGF precursor, the search of a
single VGF fragment changing early in the blood and/or in fibroblasts is our future goal, since
both tissues, unlike neuronal tissues or CSF, are easily available and may be useful for rapid
diagnosis and prognostic purposes.
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